



Lyrica® (pregabalin) – Expanded indication

- On May 23, 2019, the [FDA approved](#) Pfizer's [Lyrica \(pregabalin\)](#) capsules and oral solution as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
 - Lyrica was previously approved for this indication in patients 4 years of age and older.
- Lyrica is also approved for the management of neuropathic pain associated with diabetic peripheral neuropathy; postherpetic neuralgia; fibromyalgia; and neuropathic pain associated with spinal cord injury.
- The approval of Lyrica's expanded indication was based on a double-blind study in 140 children 1 month to less than 4 years of age with partial-onset seizures. Lyrica 7 mg/kg/day and 14 mg/kg/day were compared vs. placebo.
 - A significant improvement in partial-onset seizure rate was observed for the Lyrica 14 mg/kg/day group vs. placebo. The median percent change from baseline in seizure frequency was 70.0% with Lyrica 14 mg/kg/day vs. 22.2% with placebo ($p = 0.0223$).
 - Patients treated with Lyrica 7 mg/kg/day did not show improvement vs. placebo.
- The recommended initial dosage for Lyrica for partial-onset seizures in pediatric patients 1 month to less than 4 years of age is 3.5 mg/kg/day. The maximum dosage is 14 mg/kg/day. The dose should be administered in 3 divided doses.
 - Refer to the Lyrica drug label for dosing for all its other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.